Theravance telavancin NDA
This article was originally published in Pharmaceutical Approvals Monthly
Theravance submits telavancin for treatment of complicated skin and skin structure infections. The South San Francisco biopharmaceutical company is requesting a priority review for the injectable lipoglycopeptide antibiotic, giving it an estimated user fee date of June 7. The NDA is based on the firm's ATLAS I and ATLAS II trials, which Theravance says were "the largest clinical program ever" in CSSSIs. The company is collaborating with Astellas on development and commercialization of telavancin...
You may also be interested in...
Astellas Pharmaceuticals could enter U.S. Phase III studies with its diarrhea-predominant irritable bowel syndrome agent YM060 (ramosetron) as soon as the first half of 2008, Executive VP Toshinari Tamura told analysts during a third quarter earnings call Feb. 1
Teva has disclosed plans to focus on climate action and resilience, responsible use of natural resources and emissions, effluents and waste, as part of a long-term environmental sustainability commitment. Meanwhile, Hikma has at the same time committed “to further reducing our climate impact and improving the resilience of our business in the face of future climate change.”
Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.